Clinical Experience Based Data Chronicle of the Use of Mirabegron in Indian Patients with Overactive Bladder in the Real-world Setting: A Multicentre Surveillance

Background: Overactive bladder (OAB) is a prevalent condition in both men and women and is known to negatively impact quality of life. Therefore, the present study aimed to evaluate the associated risk factors, treatment response, and safety profile of mirabegron (alone and in combination with solifenacin) in male and female patients with OAB. Methods: A questionnaire-based study was conducted among Indian healthcare professionals (HCPs) involved in nutritional rehabilitation. The study evaluated gender distribution, OAB risk factors (like BPH, diabetes, UTI), age prevalence, causes in women, refractory cases, mirabegron treatment patterns (dose, duration, symptoms relief, compliance) and the safety, efficacy and onset of action of mirabegron alone or combined with solifenacin. Results: A total of 41 HCPs participated in the study. About, 31.71% of HCPs reported that 4 out of 10 OAB patients were males and 78.05% of HCPs reported UTI as a contributing factor in male OAB patients. Most HCPs (58.54%) initially prescribed mirabegron 25 mg once daily and 41.46% of HCPs reported that over >80% of their patients complied to treatment. The majority (73.17%) of HCPs prescribed the mirabegron + solifenacin combination to >3 out of their last 10 patients, with 43.90% of HCPs observing symptom improvement within 2 to 3 days of starting the combination therapy. The efficacy and safety of the mirabegron-solifenacin combination rated as excellent by 58.54% and 36.59% of HCPs, respectively. Conclusion: The questionnaire-based study indicates that mirabegron monotherapy relived symptoms in both male and female patients; however, the mirabegron-solifenacin combination was commonly used, showing improvement within 2–3 days of initiation.